GCTK GlucoTrack, Inc.
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a …
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Glucotrack Regains Nasdaq Equity Compliance as Strategic Transformation Advances Glucotrack (NASDAQ:GCTK) has regained compliance with Nasdaq’s stockholders’ equity requirement, with the Nasdaq Hearings Panel granting the company’s request for continued listing subject to certain conditions. The Nasdaq compliance milestone removes one specific listing issue for Glucotrack as management continues its strategic transformation, although the company said it is still working toward full compliance with all applicable Nasdaq standards. | ||
 Glucotrack Completes Lōkahi Therapeutics Business Combination, Creating AI-Driven Healthcare Platform Glucotrack has completed its business combination with Lōkahi Therapeutics, transforming the company into a Lōkahi-controlled public platform focused on acquiring and advancing healthcare assets while retaining its continuous blood glucose monitoring business as a standalone subsidiary. Key Investor TakeawaysGlucotrack (NASDAQ:GCTK) completed its strategic business combination with Lōkahi Therapeutics. | ||
 Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge. | ||